JP2025506001A5 - - Google Patents

Info

Publication number
JP2025506001A5
JP2025506001A5 JP2024546261A JP2024546261A JP2025506001A5 JP 2025506001 A5 JP2025506001 A5 JP 2025506001A5 JP 2024546261 A JP2024546261 A JP 2024546261A JP 2024546261 A JP2024546261 A JP 2024546261A JP 2025506001 A5 JP2025506001 A5 JP 2025506001A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
chelating agent
salt
mbq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024546261A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506001A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2023/051159 external-priority patent/WO2023152671A1/en
Publication of JP2025506001A publication Critical patent/JP2025506001A/ja
Publication of JP2025506001A5 publication Critical patent/JP2025506001A5/ja
Pending legal-status Critical Current

Links

JP2024546261A 2022-02-09 2023-02-09 225-アクチニウム標識錯体及びビスマス封鎖剤を含む医薬組成物 Pending JP2025506001A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263308211P 2022-02-09 2022-02-09
US63/308,211 2022-02-09
PCT/IB2023/051159 WO2023152671A1 (en) 2022-02-09 2023-02-09 Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent

Publications (2)

Publication Number Publication Date
JP2025506001A JP2025506001A (ja) 2025-03-05
JP2025506001A5 true JP2025506001A5 (cg-RX-API-DMAC7.html) 2026-02-06

Family

ID=85328574

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024546261A Pending JP2025506001A (ja) 2022-02-09 2023-02-09 225-アクチニウム標識錯体及びビスマス封鎖剤を含む医薬組成物

Country Status (5)

Country Link
US (1) US20250161502A1 (cg-RX-API-DMAC7.html)
EP (1) EP4475900A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025506001A (cg-RX-API-DMAC7.html)
CN (1) CN118647415A (cg-RX-API-DMAC7.html)
WO (1) WO2023152671A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2025058000A1 (cg-RX-API-DMAC7.html) 2023-09-13 2025-03-20
WO2025218879A1 (en) * 2024-04-15 2025-10-23 Itm Technologies Munich Se Stable formulations comprising 225-actinium labeled complexes and methods for preparing the same
WO2025255396A1 (en) * 2024-06-05 2025-12-11 Ariceum Therapeutics Gmbh Radiopharmaceutical composition and methods
WO2026089608A2 (en) 2024-10-21 2026-04-30 Erasmus University Medical Center Rotterdam Radiopharmaceuticals
WO2026120497A1 (en) * 2024-12-05 2026-06-11 Novartis Ag Stable radionuclide complex solutions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1606012A2 (en) * 2003-03-25 2005-12-21 Sloan-Kettering Institute For Cancer Research Methods for protection from toxicity of alpha emitting elements during radioimmunotherapy
KR20250057132A (ko) 2016-03-22 2025-04-28 더 존스 홉킨스 유니버시티 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제
US11478558B2 (en) * 2017-05-30 2022-10-25 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
PL3997103T3 (pl) 2019-07-08 2025-03-24 3B Pharmaceuticals Gmbh Związki zawierające ligand białka aktywującego fibroblasty i ich zastosowanie
CN118955620A (zh) 2019-07-08 2024-11-15 3B制药有限公司 包含成纤维细胞活化蛋白配体的化合物及其用途
CA3185968A1 (en) * 2020-07-13 2022-01-20 Tony Lahoutte Antibody fragment against folr1
EP4050018A1 (en) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
EP4274835A1 (en) 2021-01-07 2023-11-15 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
EP4122499A1 (en) 2021-07-23 2023-01-25 3B Pharmaceuticals GmbH Fibroblast activation protein inhibitors and use thereof

Similar Documents

Publication Publication Date Title
Van Laere et al. Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside
Westrøm et al. Preparation of 212Pb-labeled monoclonal antibody using a novel 224Ra-based generator solution
JP2025183243A (ja) 安定な濃厚放射性核種錯体溶液
JP2023552180A5 (cg-RX-API-DMAC7.html)
JP2025506322A (ja) 放射性核種錯体の大規模合成のための方法
JP2025111424A5 (cg-RX-API-DMAC7.html)
US20090155167A1 (en) Automated method
JP2023117417A5 (cg-RX-API-DMAC7.html)
RS66467B1 (sr) Kompleks koji se sastoji iz jedinjenja koje cilja psma vezano sa radionuklidom olova ili torijuma
US20250127940A1 (en) Radiopharmaceutical and methods
Le Fur et al. Pyclen tri-n-butylphosphonate ester as potential chelator for targeted radiotherapy: from yttrium (III) complexation to 90Y radiolabeling
AU2024227297A1 (en) Methods for radiolabeling PSMA binding ligands and their kits
Matazova et al. Insights into actinium complexes with tetraacetates─ AcBATA versus AcDOTA: thermodynamic, structural, and labeling properties
US20250145664A1 (en) Pharmaceutical compositions for imaging, diagnosis and treatment of cancer
Holland The radiochemistry of zirconium
WO2026025213A1 (zh) 一种含rgd多肽的组合物及其应用
Srivastava et al. Targeted Radiopharmaceuticals and Imaging: Development Challenges and Opportunities
RU2859685C2 (ru) Фармацевтическая композиция в форме раствора для внутривенного введения на основе металлокомплексов бета-эмиттеров: лютеций-177 или тербий-161 и агонистов соматостатиновых рецепторов: DOTA-TATE, DOTA-TOC, DOTA-NOC
Pandey et al. Advances in Targeted Radiopharmaceuticals: Challenges and Opportunities
WO2025030160A1 (en) Chelating compounds and methods of uses thereof
AU2023227218A1 (en) Radiopharmaceutical and methods
Notation Radioactivity, Radionuclides, and Radiopharmaceuticals
Test Asian Journal of Medical Radiological Research Original Article